Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, March 31, 2023.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2023 (2023-03-31): -330.92%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-179.08%
RETURN ON EQUITY (ROE) AVG 3Y
-124.26%
RETURN ON EQUITY (ROE) AVG 5Y
-335.67%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Atara Biotherapeutics, Inc.
Market Cap
$84.70M
Return on Equity (ROE)
N/A
TTM Avg
-179.08%
3Y Avg
-124.26%
5Y Avg
-335.67%
Market Cap
$84.75M
Return on Equity (ROE)
-85.65%
TTM Avg
-57.41%
3Y Avg
-45.73%
5Y Avg
-8.61%
Market Cap
$84.00M
Return on Equity (ROE)
-309.44%
TTM Avg
-515.53%
3Y Avg
-464.77%
5Y Avg
-329.14%
Market Cap
$83.96M
Return on Equity (ROE)
-50.80%
TTM Avg
-124.86%
3Y Avg
-88.30%
5Y Avg
-60.21%
Market Cap
$83.49M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$86.69M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
Market Cap
$87.86M
Return on Equity (ROE)
-150.95%
TTM Avg
-77.89%
3Y Avg
-62.90%
5Y Avg
-47.80%
Market Cap
$81.22M
Return on Equity (ROE)
-114.06%
TTM Avg
-50.52%
3Y Avg
-45.18%
5Y Avg
-45.18%
Market Cap
$88.21M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | $84.70M | N/A | -179.08% | -124.26% | -335.67% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | -85.65% | -57.41% | -45.73% | -8.61% |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -309.44% | -515.53% | -464.77% | -329.14% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | -50.80% | -124.86% | -88.30% | -60.21% |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 45.93% | 16.96% | -19.36% | -13.87% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -150.95% | -77.89% | -62.90% | -47.80% |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | -114.06% | -50.52% | -45.18% | -45.18% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 2.51% | -5.84% | -10.75% | -7.81% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | -1542.57% | -254.55% | -187.52% | -143.69% |
ROE
N/A
ROA
-79.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2023-03-31 | -330.92% |
| 2022-12-31 | -180.28% |
| 2022-09-30 | -132.05% |
| 2022-06-30 | -96.18% |
| 2022-03-31 | -155.99% |
| 2021-12-31 | -121.65% |
| 2021-09-30 | -105.79% |
| 2021-06-30 | -95.85% |
| 2021-03-31 | -78.05% |
| 2020-12-31 | -66.32% |
| 2020-09-30 | -85.84% |
| 2020-06-30 | -248.85% |
| 2020-03-31 | -638.49% |
| 2019-12-31 | -757.72% |
| 2019-09-30 | -918.51% |
| 2019-03-31 | -899.90% |
| 2018-12-31 | -680.82% |
| 2018-09-30 | -461.48% |
| 2018-06-30 | -350.80% |
| 2018-03-31 | -308.03% |
| 2017-12-31 | -671.81% |
| 2017-09-30 | -497.26% |
| 2017-06-30 | -437.23% |
| 2017-03-31 | -378.07% |
| 2016-12-31 | -311.54% |
| 2016-09-30 | -303.71% |
| 2016-06-30 | -236.20% |
| 2016-03-31 | -212.69% |
| 2015-12-31 | -181.60% |
| 2015-09-30 | -139.33% |
| 2015-06-30 | -271.69% |
| 2015-03-31 | -181.33% |
| 2014-12-31 | -271.42% |
| 2014-06-30 | -313.96% |
